Neuropilin-1-peptide based antibody, highliting new epitope associated to glycosaminoglycan-modified neuropilin-1 and methods of use thereof

Abstract

The present disclosure relates to the field of NRP-1 peptides vaccines corresponding to epitopes associated to diseases and capable to trigger the immune response such as production of anti-NRP-1 antibodies with specificity to GAG-modified NRP-1 that are able to block DNA damages response (DDR). In particular, NRP-1 peptides vaccines and their derived anti-NRP-1 antibodies (NRP-1 peptides antibodies) specific for an epitope located in the binding domain of leptin on NRP-1 that are able to enter into the nucleus and to block DNA damages response (DDR) and having properties of interest in the treatment of diseases involving NRP-1/OBR complex. The NRP-1 peptide vaccines and the NRP-1 peptides antibodies are of interest in diagnosis and therapies; especially in diseases related to DNA Damage Response and Glycosaminoglycans.

Dependencies are inferred from the claim text.